EW · News · 20260807N

Guidance / Outlook

Edwards Lifesciences Corp · 2026-08-07 · Importance 28 · Surprise 42 · In source text

Edwards Lifesciences provided optimistic guidance for the third quarter and full year 2026. The reporting did not specify the associated revenue, margin, or earnings targets. The company’s latest reported revenue was approximately $1.74 billion, but no separate financial impact from the updated outlook was disclosed.

Key facts

• The company provided optimistic Q3 and full-year 2026 guidance. source
• Company insiders have been net sellers, offloading 43,539 shares worth approximately $3.69 million in the last 90 days. source
• Average 12-month price target: $100.27. source
• Edwards Lifesciences has received a "Moderate Buy" consensus rating from 23 brokerages. source
• Current share price reported in the digest: $89.33. source

Impact estimates